Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

P. Kelly, F. Paulin, D. Lamont, L. Baker, S. Clearly, D. Exon, A. Thompson

    Research output: Contribution to journalArticle

    30 Citations (Scopus)

    Abstract

    BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.

    METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).

    RESULTS: Plasma protein peaks were identified that differed significantly (P<0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.

    CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK

    Original languageEnglish
    Pages (from-to)955-961
    Number of pages7
    JournalBritish Journal of Cancer
    Volume106
    Issue number5
    DOIs
    Publication statusPublished - 28 Feb 2012

    Cite this

    Kelly, P., Paulin, F., Lamont, D., Baker, L., Clearly, S., Exon, D., & Thompson, A. (2012). Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. British Journal of Cancer, 106(5), 955-961. https://doi.org/10.1038/bjc.2012.15
    Kelly, P. ; Paulin, F. ; Lamont, D. ; Baker, L. ; Clearly, S. ; Exon, D. ; Thompson, A. / Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. In: British Journal of Cancer. 2012 ; Vol. 106, No. 5. pp. 955-961.
    @article{b1bbe1431f414959802efd9b34364ae7,
    title = "Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer",
    abstract = "BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).RESULTS: Plasma protein peaks were identified that differed significantly (P<0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK",
    author = "P. Kelly and F. Paulin and D. Lamont and L. Baker and S. Clearly and D. Exon and A. Thompson",
    year = "2012",
    month = "2",
    day = "28",
    doi = "10.1038/bjc.2012.15",
    language = "English",
    volume = "106",
    pages = "955--961",
    journal = "British Journal of Cancer",
    issn = "0007-0920",
    publisher = "Cancer Research UK",
    number = "5",

    }

    Kelly, P, Paulin, F, Lamont, D, Baker, L, Clearly, S, Exon, D & Thompson, A 2012, 'Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer', British Journal of Cancer, vol. 106, no. 5, pp. 955-961. https://doi.org/10.1038/bjc.2012.15

    Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. / Kelly, P.; Paulin, F.; Lamont, D.; Baker, L.; Clearly, S.; Exon, D.; Thompson, A.

    In: British Journal of Cancer, Vol. 106, No. 5, 28.02.2012, p. 955-961.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

    AU - Kelly, P.

    AU - Paulin, F.

    AU - Lamont, D.

    AU - Baker, L.

    AU - Clearly, S.

    AU - Exon, D.

    AU - Thompson, A.

    PY - 2012/2/28

    Y1 - 2012/2/28

    N2 - BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).RESULTS: Plasma protein peaks were identified that differed significantly (P<0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK

    AB - BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).RESULTS: Plasma protein peaks were identified that differed significantly (P<0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK

    U2 - 10.1038/bjc.2012.15

    DO - 10.1038/bjc.2012.15

    M3 - Article

    VL - 106

    SP - 955

    EP - 961

    JO - British Journal of Cancer

    JF - British Journal of Cancer

    SN - 0007-0920

    IS - 5

    ER -